 |
|
|
| |
MK-5172, a Second Generation HCV NS3/4A Protease Inhibitor is Active Against Common Resistance Associated Variants
(RAVs) and Exhibits Cross-Genotype Activity
|
| |
| |
Reported by Jules Levin AASLD 2011 San Francisco Nov 6-9
Donald Graham, Adriana Acosta, Zhuyan Guo, John A. Howe, Robert Ogert, Michael Miller, Daria Hazuda, David Olsen, Steven Ludmerer,
Julie M Strizki and Richard J.O. Barnard
Merck and Co, Whitehouse Station, NJ, USA
|
| |
|
|
|
|
|
